Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Southern California
Masonic Cancer Center, University of Minnesota
Baylor College of Medicine
Rutgers, The State University of New Jersey
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.